HYBRID EVENT: You can participate in person at Rome, Itlay or Virtually from your home or work.

11th Edition of International Conference on

Neurology and Neurological Disorders

June 05-07, 2025 | Rome, Italy

Neuroprotective Agents

Neuroprotective Agents

Neuroprotective agents refer to compounds and drugs that are used to protect neurons and other cells of the nervous system from damage and diseases. The concept of neuroprotection was introduced in the 1980s and has since become an increasingly important field of research in neuroscience. Neuroprotection is a complex process that involves a number of different factors, such as the prevention of neurotoxin accumulation, the promotion of neuronal survival or regeneration, the inhibition of apoptosis, and the control of inflammatory cascades. Neuroprotection is thought to be triggered by a variety of different stimuli, including oxidative stress, glutamate excitotoxicity, and calcium dysregulation. One approach to protection of the nervous system is to target the neurotoxins, such as those secreted by activated glia. Inhibition of excitotoxicity can be reached by both antagonizing glutamate receptors or blocking its receptors from binding the agonists. Many drugs have been developed that target neurological receptors, reducing the influx of calcium and reducing intracellular calcium levels. Another approach is to target cell survival and regenerative pathways. Neurotrophic factors such as nerve growth factor (NGF) are able to promote neurogenesis and neuronal survival. In addition, antioxidants are proposed to reduce oxidative damage and perceived age-related diseases of the CNS. The use of both natural and synthetic compounds, such as vitamins, minerals, plant extracts, and herbal derivatives, has been proposed in the treatment of neurodegenerative diseases. It is important to understand that not all treatments are equal and that careful selection is necessary to find an effective and safe neuroprotective agent. It is also important to consider potential side effects of any of the agents and whether they will hamper the therapeutic effect. Ultimately, it is up to the patient and the healthcare provider to decide which neuroprotective agent is best for the given situation.

Committee Members
Speaker at Neurology and Neurological Disorders 2025 - Ken Ware

Ken Ware

NeuroPhysics Therapy Institute, Australia
Speaker at Neurology and Neurological Disorders 2025 - Robert B Slocum

Robert B Slocum

University of Kentucky HealthCare, United States
Speaker at Neurology and Neurological Disorders 2025 - Luiz Moutinho

Luiz Moutinho

University of Suffolk, United Kingdom
Neurology 2025 Speakers
Speaker at Neurology and Neurological Disorders 2025 - David Lominadze

David Lominadze

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Milton C R Medeiros

Milton C R Medeiros

Irmandade Santa Casa de Arapongas PR, Brazil
Speaker at Neurology and Neurological Disorders 2025 - Sang Hie Lee

Sang Hie Lee

University of South Florida, United States
Speaker at Neurology and Neurological Disorders 2025 - Sergei M Danilov

Sergei M Danilov

University of Illinois, United States

Submit your abstract Today

Watsapp